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Although treatment of human macrophages or fibroblasts with human gamma interferon results in the
inhibition of intracellular Toxoplasma gondii, murine gamma interferon stimulated only murine macrophages,
not murine fibroblasts, to inhibit T. gondii. This species difference may be important in understanding the
control of acute and chronic toxoplasmosis.
Gamma interferon (IFN--y) is a multifunctional molecule
with species-specific immunomodulation and antiviral and
antiprotozoal activities which likely function by different
mechanisms (6). The mechanism of IFN-y antiviral activity
has been at least partially defined (6). It has been suggested
recently that IFN-y is the key factor in the in vivo control of
Toxoplasma gondii in the mouse (16). Human IFN-y has
been shown to inhibit T. gondii in both human macrophages
(5) and human fibroblasts (10). The mechanism of inhibition
of T. gondii growth in human fibroblasts is the induction of
an indoleamine 2,3-dioxygenase which degrades tryptophan
and starves the obligate intracellular parasite (7, 10). The
antitoxoplasma state induced by IFN--y in human macro-
phages may be similar, or other mechanisms may be in-
volved. We have examined the effect of murine recombinant
IFN-y on the growth of intracellular T. gondii in mouse
fibroblasts and found that this IFN--y does not suppress
intracellular growth and does not induce indoleamine 2,3-
dioxygenase in these cells.
Murine IFN--y produced in Escherichia coli was donated
by Schering Corp. as part of the American Cancer Society
Program on Interferon Research. IFN--y batch 18563-051 was
dissolved in 5 mM Tris hydrochloride-0.25 M NaCl-0.05%
2-mercaptoethanol-50% glycerol, pH 7.4, and stored at
-20°C at a final concentration of 0.6 mg/ml. The N terminus
of the IFN-y was Cys-Tyr-Cys. The IFN--y was assayed for
antiviral activity by its ability to prevent lysis of L-929 cells
or primary ICR mouse fibroblasts by vesicular stomatitis
virus and was found to be equivalent to 1.0 U/ng when
compared with National Institute of Allergy and Infectious
Disease international reference murine IFN--y (National In-
stitutes of Health catalog no. GgO2-901-533).
T. gondii isolates of the recloned RH strain were grown in
human foreskin fibroblasts as described previously (11). For
assay of interferon effect, parasites just released from host
cells were counted in a hemacytometer; approximately 5 x
104 PFU were transferred to 4-cm2 monolayers of L-929 or
normal ICR mouse fibroblasts that had been treated for 24 h
with various concentrations of IFN--y diluted in RPMI 1640
(GIBCO Laboratories) supplemented with 2% fetal bovine
serum (HyClone Laboratories, Inc.). The parasites were
allowed to infect the cells, and the intracellular growth of T.
gondii was measured by the incorporation of [5,6-3H]uracil
(2 ,Ci/ml, 48.6 Ci/mmol; Dupont, NEN Research Products).
The incorporation of this compound is specific for the
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parasite and correlates with intracellular growth (12). After 4
to 18 h, the monolayers were lysed in 1% sodium dodecyl
sulfate-100 mM uracil in Hanks balanced salt solution and
processed for the recovery of acid-precipitable radioactivity
as described previously (14).
The degradation of tryptophan by intact cells treated with
IFN-y was measured in confluent monolayers grown in
0.3-cm2 wells. IFN--y and 0.6 ,uCi of L-[methylene-'4C]
tryptophan (53.5 mCi/mmol; Amersham Corp.) per ml were
added to the medium at the same time. Four days later, the
medium was analyzed by ascending paper chromatography
in 0.1 N HCl and the distribution of radioactivity between
tryptophan and kynurenine was determined (9). Indoleamine
2,3-dioxygenase was assayed in sonic extracts of L-929
cells or ICR mouse fibroblasts by a sensitive radiometric
procedure that depended on the enzymatic conversion of L-
[methylene-14C]tryptophan to N-[14C]formylkynurenine and
subsequent acid degradation of this product to [14C]kynuren-
ine (13).
Figure 1 shows the results of two representative indepen-
dent experiments using Schering IFN--y to assay T. gondii
inhibition in L-929 cells. Over a broad range of IFN--y
concentrations, there was no statistically significant inhibi-
tion of T. gondii growth compared with untreated controls.
In other experiments (data not shown), IFN--y concentra-
tions of up to 2,000 U/ml had no inhibitory effect. IFN--y
from the same lot assayed on the same cell line in the same
medium showed the expected antiviral effect against vesic-
ular stomatitis virus (3).
The induction of indoleamine 2,3-dioxygenase was mea-
sured in L-929 cells and ICR fibroblasts. Cultures were
treated with up to 2,000 U of IFN--y per ml for 2 days before
sonic extracts were prepared. No significant enzyme activity
was detected. Both control and IFN--y-treated cells had
activities of <0.05 nmol of N-formylkynurenine/min per mg
of protein. In contrast, treatment of human fibroblasts for 2
days with 32 U of human IFN--y per ml raises the enzyme
level from undetectable to 1.5 nmol/min per mg of protein
(9). Consistent with the inability of IFN--y to induce murine
indoleamine 2,3-dioxygenase, we observed no interferon-
induced degradation of tryptophan in the medium of L-929
cells treated for 4 days with 200 U of murine IFN--y per ml.
Human fibroblasts treated with 4 U of human IFN-y per ml
for 2 days show complete degradation of tryptophan in the
medium (7). The same lot of IFN--y had the expected
inhibitory effect on intracellular replication of T. gondii in
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FIG. 1. Two independent experiments with various concentra-
tions of IFN-y on monolayers of L-929 cells infected with equal
inocula of T. gondii. The uracil incorporation data are normalized to
100 against the control lacking IFN-y. Error bars represent standard
deviations of three replicates.
treated with 20 U of IFN-y per ml; 2.96 ± 1.8 (standard
deviation) parasites per cell were counted in controls, com-
pared with 0.11 ± 0.17 parasites per cell in treated cultures
after 24 h.
Previous work has established the activity and mode of
action of human IFN--y against T. gondii in human fibroblasts
(5, 7, 9, 10, 13); IFN--y activates human macrophages to
inhibit T. gondii (5), but the mechanism of inhibition may not
be the same as has been demonstrated in nonmacrophage
cell lines because supplementation of tryptophan reverses
only a small portion of IFN--y-mediated inhibition, and
mouse macrophages stimulated by IFN-y inhibit T. gondii
but do not degrade tryptophan (4). Our results indicate that
IFN--y does not directly empower mouse fibroblasts to
inhibit intracellular T. gondii. Our findings are in conflict
with previous reports (4, 15) that murine type II interferon
inhibits T. gondii in infected L-929 cells. The interferon used
in these earlier experiments was produced from mouse
spleen cells stimulated by T. gondii, concanavalin A, or
mycobacterial antigens. Our results suggest that pure IFN-Y
may not be responsible for the reported effect. Data similar
to those presented here, but using mouse 3T3 cells and
recombinant murine IFN--y prepared by Genetech Inc., were
noted in a review of the antitoxoplasma activity of human
IFN-y (8).
It has been shown recently that antibody to IFN--y can
modulate in vivo survival of acute T. gondii infection in
BALB/c mice (16). Our studies suggest that mice can control
acute (but not necessarily chronic) T. gondii infection en-
tirely by macrophages, that infection of cells other than
macrophages is not important to the survival of the host, or
that infection of nonmacrophage cells is controlled by a
mechanism other than the direct production of an antipara-
sitic state by IFN--y. IFN--y-stimulated macrophages may
produce a monokine that inhibits T. gondii intracellular
growth in fibroblasts and other cell types. Such an inhibitor,
possibly specific for T. gondii, has been demonstrated in the
mouse model (2). Lymphokines and monokines may there-
fore inhibit T. gondii replication by more than one mecha-
nism. Susceptibility of inbred mouse strains to T. gondii
infection varies (1). Species and intrastrain differences may
give useful clues to the pathobiology of this infection.
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